Background: Outcome of pseudomyxoma peritonei (PMP) after cytoreductive surgery (CRS) and hypertermic intraperitoneal chemotherapy (HIPEC) is heterogeneous even after adjusting for clinico-pathological prognostic variables. The identification of additional prognostic or even predictive biomarkers is an unmet clinical need.
introduction Pseudomyxoma peritonei (PMP) is an extremely rare condition characterized by progressive accumulation of mucinous ascites and tumor implants throughout the peritoneum with an incidence of 1-2 per million per year [1] . It has been recently demonstrated that most PMP originate from mucinous appendiceal neoplasms. Survival improvement has been reported with a strategy combining cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat macroscopic and microscopic disease, respectively. Outcome following curative surgery is predominantly determined by the completeness of cytoreduction (CC), peritoneal carcinomatosis index (PCI) and pathological grade-although the latter has been categorized using different and often inconsistent classifications [2] [3] [4] . Despite the low-malignant potential, PMP comprises a heterogeneous group of neoplasms with highly variable biologic behavior and up to 30% of patients will die due to progressive disease. It is conceivable that prognosis of PMP may be related to the individual molecular profile. Therefore, prognostic and predictive biomarkers are urgently needed for improving the management of patients with this orphan disease.
Appendiceal mucinous neoplasms show one of the highest prevalence of KRAS mutations among human cancers and may drive the progression of PMP [4] [5] [6] [7] [8] . GNAS mutations are also frequently observed in low-grade appendiceal mucinous tumors and may play a crucial role in mucin production in patients with PMP [9, 10] . Therefore, even if the knowledge of the molecular landscape of PMP is evolving, the clinical impact of specific gene mutations is still poorly understood. This is due to the rarity of the disease, heterogeneity of patients' series and lack of standardization of the techniques used for mutational analysis.
In this study, we aimed at investigating the prognostic role of KRAS and GNAS mutations, as detected by next-generation sequencing (NGS), in PMP patients undergoing CRS and HIPEC.
materials and methods patients
All 40 patients included in the mono-institutional training cohort were treated with CRS and HIPEC at Fondazione IRCCS Istituto Nazionale dei Tumori of Milan from 2004 up to December 2014. CRS included peritonectomy procedures and multivisceral resections aiming at removing the macroscopic disease, according to the technique described by Sugarbaker [11] . Closed abdomen HIPEC was carried out using cisplatin and mitomycin C as previously reported [2] . Institutional follow-up guidelines were adopted in all patients, with thorax-abdomen CT scan and tumor markers (CEA, CA 19-9 and CA 125) carried out every 6 months until the fifth year and annually thereafter.
On pathological review done by two blinded pathologists, only mucinous neoplasms of appendiceal origin according to WHO classification were considered eligible for the present study.
Other eligibility criteria were as follows: (i) complete follow-up data at our institution; (ii) follow-up of at least 5 years from the surgery in progression-free patients; (iii) complete clinical data; (iv) availability of paraffin-embedded blocks with sufficient cellularity for molecular analysis; and (v) signed informed consent for alive patients. The following clinical parameters were chosen for prognostic analysis according to data literature: gender, age, previous systemic chemotherapy, pathological grade, PCI and CC [12] . This study received IRB approval.
The validation cohort comprised 25 patients: 18 treated at our institution and 7 at Drexel University College of Medicine, Philadelphia. Eligibility criteria were the same used for the training set, except for the reduction in the follow-up cut-off from 5 to 3 years.
next-generation sequencing
The 50-gene Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies) with the Ion-Torrent™ Personal Genome Machine platform (Life Technologies) was used in all experiments, as described in the supplementary materials, available at Annals of Oncology online.
statistical analysis
The differences of significance across categorized groups were compared using the χ 2 test or Fisher's exact test when appropriate. Progression-free survival (PFS) was defined as the time period between the date or CRS and the date of death or the date of first progression, whichever occurred first. Overall survival (OS) was defined as the time between the date or CRS and the date of death from any cause or the date of the last follow-up. Analysis of the survival curves was carried out using the Kaplan-Meier survival analysis and differences in survival distributions according to molecular parameters were tested using log-rank statistics. A P value of 0.05 by the univariate analysis was adopted as enter criteria for the multivariate analysis using the Cox proportional hazard model. The final model was obtained by the selection of independent predictors of PFS by means of backward elimination method. P values <0.05 were considered significant. We did not perform prognostic analysis in terms of OS due to a limited number of events (7 patients died). The statistical software used was SPSS 20.0 (SPSS, Inc., Chicago, IL).
results

patient population
Data for this study were collected from a prospective institutional database that has gathered information from 230 patients from 2004. Figure 1 shows detailed analysis of the selection process of the study population. After exclusion of patients non-fulfilling the inclusion criteria and the inadequate tumor samples, the final study population (training cohort) included a total of 40 assessable patients. Patients and disease characteristics are listed in Table 1 Table 1 .
results of NGS
Exon 2 KRAS mutations were detected in 29 (72%) samples, while exon 8 GNAS mutations were detected in 21 (52%). The relative proportion of different hotspot mutations is summarized in supplementary Table S1 , available at Annals of Oncology online ( panel A, study population; panel B, validation cohort).
In the study population, KRAS mutation was not significantly associated with the other variables, including age, gender, CC, PCI or pathological grade. On the other hand, the presence of GNAS mutation was associated with incomplete cytoreduction (P = 0.05). Most importantly, GNAS mutations were associated with KRAS mutations (P = 0.002). Neither KRAS nor GNAS mutational status was associated with pathological grade (P = 0.338 and 0.427, respectively). Table 2 shows the type of mutations found in each patients with their relative allele frequencies. The median KRAS mutant allelic fraction was 9% (range 1%-57%), and was <10% cut-off in 16 (55%) cases. Similarly, the median GNAS mutant allelic fraction was 11% (range, 4%-57%) and was <10% cut-off in 9 (43%).
Interestingly, additional mutations beyond KRAS and GNAS were found. Among others, we observed mutations in TP53 in five cases, as well as mutations in PI3K/AKT/mTOR pathways in five (including three PI3KCA, one AKT and one LKB1 mutation) and mutations in angiogenic tyrosine kinase receptors, such as FGFR3 and PDGFRA.
survival outcomes
After a median follow-up of 68.1 months, 25 patients had a documented disease progression and only 7 patients died of disease. Five-year survival and median PFS were 41.2% and 37.4% months, respectively. Five-year OS was 89% and the median OS was not reached (Figure 2A and B) .
At univariate analysis, the variables correlated with PFS were CC, PCI, KRAS status and GNAS status (Table 3 ). Figure 3 shows the Kaplan-Meier curves for PFS according to KRAS and GNAS mutational status ( Figure 3A and B, respectively) . The Cox hazard model identified only PCI>20 [hazard ratio (HR): 4.32, 95% confidence interval (CI) 1.28-14.55, P-value: 0.018] and KRAS mutation (HR: 14.96, 95% CI 1.95-114.77) as independent predictors of PFS. Neither CC nor GNAS mutation resulted to be independently correlated with PFS (Table 3) . Interestingly, our initial results were validated in an independent cohort of 25 patients (supplementary Figure S1 and Table S2 , available at Annals of Oncology online). Briefly, KRAS mutation was again an independent prognostic variable maintaining a significant impact on PFS in multivariate analysis (P = 0.029).
By grouping the KRAS-mutated cases in the study and validation populations, we explored whether KRAS mutational rate may have a prognostic impact. The median KRAS mutant allelic fraction was 10% and was adopted as a cut-off. However, patients with KRAS mutant allelic fraction ≥10% did not show a poorer median PFS when compared with those with rate <10% (20.5 versus 23 months; HR 0.78, 95% CI 0.39-1.57; P = 0.486). A subset analysis in the KRAS-mutated population failed to show any survival impact of coexisting events in GNAS, PI3KCA and TP53.
discussion
In this study, we showed that KRAS mutations, but not GNAS mutations, are associated with poorer outcome following CRS and HIPEC in PMP patients. Despite its indolent behavior, some adverse prognostic factors have been validated, including advanced age, PCI≥20, incomplete cytoreduction, high pathological grade and use of preoperative chemotherapy [12] . Since prognosis is extremely heterogeneous even after adjusting for these clinical and pathological variables, it is conceivable that disease behavior may be also linked to molecular features.
The pathological classification of mucinous appendiceal neoplasms and the associated PMP syndrome has been a controversial issue. The recent international consensus conducted by Peritoneal Surface Oncology Group International managed to build an agreement on PMP classification [13] . However, the problem of variability of inter-and intra-observer still persists, even in the case of well-trained pathologists. Mutational analyses can overcome the limitations of morphological assessment, given the higher level of reproducibility and objectiveness. Moreover, several studies including ours showed that KRAS and GNAS mutations are independent from pathological grade [9, 10, [14] [15] [16] .
It is well known that KRAS and GNAS mutations play a predominant role in the development of mucinous tumors of several districts, including the appendix [5-7, 9, 10, 14, 15] . We showed for the first time that KRAS mutations were independently associated with poorer PFS of PMP patients following CRS and HIPEC. Most importantly, we were able to validate our results by analyzing an independent cohort of patients. Conversely, the poor prognostic effect of GNAS mutation observed at univariate analysis was not retained at the multivariate model. The conduction of translational studies in PMP is not straightforward and hampered by several factors such as the low incidence of the disease, wide range of prognostic features of the tumor, variety of pathological classification, heterogeneity of the treatments and differences in the techniques used for gene sequencing.
The few studies published thus far have not shown a prognostic role of KRAS mutations. The first used a highly sensitive technique, i.e. the mutant-enriched polymerase chain reaction (PCR). The patients included were 64, but no data on disease stage and type of surgery were available [7] . The second study involved patients undergoing standard CRS (with or without HIPEC) [4] , but KRAS mutations were assessed in a subgroup of 111 patients of the overall population. However, the method of assessment was direct Sanger sequencing, which has a sensitivity cut-off of 10%. In a more recent series from a highly specialized center, both KRAS and GNAS mutations were not shown to be prognostic in patients with disseminated appendiceal mucinous neoplasms. The limitation of the study was the inclusion of all-grades histologies, including grade 3 adenocarcinomas and signet-ring histology, and the use of Sanger sequencing [16] . Our data are in contrast with these studies, excepting for GNAS, that was not independently correlated with PFS. The lack of prognostic value of GNAS mutations could be attributed to its frequent association with KRAS mutations. Although these genes are related to different aspects of molecular mechanisms underlying tumor development, they present a sort of redundant and collinear effect on PFS from the statistical standpoint.
One possible criticism to our study is that of a possible selection bias due to technical issues. It is well known that the cellularity of PMP is extremely low, hampering the results of translational or preclinical studies. Therefore, it could be reasonable to speculate that we included cases with higher cellularity and other biological features that may have favored the success of the mutational analysis. However, the hypothesis of a skewed sample of patients was excluded as the 5-year OS and PFS of 89% and 41%, respectively, were perfectly in line with literature data (Figure 2) . Furthermore, in contrast to the traditional Sanger sequencing that has a limited reliability in cases with fraction of mutated alleles of <10%, the NGS approach is, beyond any doubt, much more sensitive with a capability to detect mutations present in as few as 1% of tumor cells [17] . Our data have shown that KRAS and GNAS mutant allelic fractions were <10% cut-off in about half of our samples, likely due to the scarce quantity of epithelial cells within abundant mucinous deposits. Differently from colorectal cancer, KRAS mutant allelic fraction did not seem to have a prognostic effect [18] . However, the most important issue is that NGS or mutantenriched PCR are clearly the most appropriate techniques to obtain accurate data and to avoid false-negative results. KRAS mutations were found in all samples included in a previous NGS-based study [10] , even if the 100% mutation positivity may partly be the result of a selection bias. Finally, our study allowed us to obtain valuable data regarding the presence of new and potentially targetable mutations in this orphan disease. In particular, this may be of particular interest for future development of newer medical treatments in unresectable patients [10, 19] . Although the occurrence of PI3KCA and AKT mutations was already known [10] , we showed for the first time the presence of an LKB1 mutation possibly linked to activation of mTOR pathway. Also, the involvement of SMAD4 was already described [10, 19] . Interestingly, we discovered new mutations in angiogenic tyrosine kinase receptors such as FGFR3 or PDGFRA, which may be targeted by specific inhibitors. Further limitations of our study are constituted by the retrospective nature and the small sample size. The effect on OS could not be investigated due to low number of events-which is consistent with the indolent course of the disease.
In conclusion, KRAS mutations were independently prognostic for PFS in PMP patients undergoing curative peritonectomy and HIPEC. The conduction of further studies on tumor profiling should be strongly encouraged in referral centers to increase the available knowledge on disease development and progression, to develop a molecular classification and to validate new prognostic and/or predictive biomarkers. Even if validated, our results should be still viewed with caution, considering the limitations to generalize the prognostic role of KRAS mutations to common clinical scenarios.
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